Harbin Gloria Pharmaceuticals Co., Ltd.
誉衡药业
002437
Shenzhen Stock Exchange
Company Profile
Against the new normal of high-quality development, the Company pursues progress while maintaining stability and continuously enhances its core competitive strengths. 1. Corporate Culture and Development Philosophy The Company upholds the culture of “More Splendid Because of You”, featuring respect, growth, passion, cooperation and sharing, which has been integrated into all operations. Since 2023, guided by the “Second Startup” and the values of Responsibility, Endeavor, Truth-Seeking, Efficiency, Innovation and Sharing, the Company adopts elite governance and the “Product-Centric” strategy, committed to building an international enterprise with sound assets, strong profitability and independent innovation capacity. 2. Product Advantages Following the “Product-Centric” strategy, the Company has built a diversified product portfolio via introduction, R&D cooperation, investment and M&A. It holds over 300 drug registration certificates covering musculoskeletal, cardiovascular, anti-tumor and other major therapeutic areas. 214 products are included in the 2025 National Medical Insurance Catalog and 62 in the Essential Medicines Catalog. Core products lead their segments with top market shares, and An’nao Pills/Tablets are exclusive TCM essential drugs. 3. Production, Technology and Quality Advantages With six manufacturing subsidiaries, the Company has formed an integrated API and formulation production system with more than 50 production lines. It boasts advanced technology, process patents, and strong R&D and pilot-scale capabilities. A full life-cycle quality management system in line with latest GMP standards ensures strict quality control and drug safety. 4. Operational Management Advantages Supported by scientific decision-making and refined management, the Company achieves industry-leading asset efficiency. Its asset-liability ratio and administrative expense ratio have dropped to the lowest levels in years, with operating costs significantly reduced. Information-based construction optimizes processes and supports steady long-term development.
Full description
Harbin Gloria Pharmaceuticals Co., Ltd (hereinafter referred to as the “Company”) has achieved advantages in wide coverage on therapeutic areas and product portfolio by in-licensing, co-development of products, mergers and acquisitions in the past few years. By far, the Company has formed a relatively strong product portfolio in the following therapeutic areas (being areas of musculoskeletal system, cardiovascular system, vitamin and mineral supplements, electrolytes, anti-infection and anti-tumor, which assures the Company of a leading industry position and competitive advantages in areas mentioned above. The Company’s core business remained to be pharmaceutical manufacturing.